Versor Investments LP Has $220,000 Stake in Orthofix Medical Inc. $OFIX

Versor Investments LP trimmed its position in shares of Orthofix Medical Inc. (NASDAQ:OFIX) by 52.8% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 13,500 shares of the medical device company’s stock after selling 15,100 shares during the period. Versor Investments LP’s holdings in Orthofix Medical were worth $220,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in OFIX. Juniper Investment Company LLC increased its holdings in Orthofix Medical by 123.5% during the fourth quarter. Juniper Investment Company LLC now owns 1,937,249 shares of the medical device company’s stock worth $33,824,000 after buying an additional 1,070,656 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Orthofix Medical by 31.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 659,475 shares of the medical device company’s stock valued at $11,515,000 after purchasing an additional 159,177 shares during the last quarter. Emerald Mutual Fund Advisers Trust increased its holdings in shares of Orthofix Medical by 35.4% in the fourth quarter. Emerald Mutual Fund Advisers Trust now owns 503,802 shares of the medical device company’s stock valued at $8,796,000 after purchasing an additional 131,653 shares during the last quarter. Boone Capital Management LLC increased its holdings in shares of Orthofix Medical by 13.6% in the fourth quarter. Boone Capital Management LLC now owns 1,057,313 shares of the medical device company’s stock valued at $18,461,000 after purchasing an additional 126,806 shares during the last quarter. Finally, Nuveen LLC acquired a new position in shares of Orthofix Medical in the first quarter valued at $1,445,000. 89.76% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Aviva Mcpherron sold 3,728 shares of Orthofix Medical stock in a transaction that occurred on Wednesday, June 18th. The shares were sold at an average price of $10.51, for a total transaction of $39,181.28. Following the sale, the insider directly owned 46,322 shares in the company, valued at $486,844.22. This trade represents a 7.45% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.30% of the stock is currently owned by corporate insiders.

Orthofix Medical Stock Performance

OFIX opened at $14.55 on Friday. The stock has a market capitalization of $574.58 million, a price-to-earnings ratio of -4.59 and a beta of 0.82. The company has a quick ratio of 1.50, a current ratio of 2.67 and a debt-to-equity ratio of 0.38. The company has a 50-day simple moving average of $11.74 and a 200 day simple moving average of $13.63. Orthofix Medical Inc. has a twelve month low of $10.24 and a twelve month high of $20.73.

Orthofix Medical (NASDAQ:OFIX) last issued its earnings results on Tuesday, August 5th. The medical device company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.40). Orthofix Medical had a negative net margin of 15.29% and a negative return on equity of 25.43%. The company had revenue of $203.12 million during the quarter, compared to analyst estimates of $196.89 million. Orthofix Medical has set its FY 2025 guidance at EPS. Analysts predict that Orthofix Medical Inc. will post -2.81 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Wall Street Zen upgraded shares of Orthofix Medical from a “sell” rating to a “hold” rating in a report on Saturday, August 9th. JMP Securities reiterated a “market perform” rating on shares of Orthofix Medical in a report on Friday, June 6th. Finally, Barrington Research upgraded shares of Orthofix Medical to a “strong-buy” rating and set a $16.00 price objective on the stock in a report on Monday, June 23rd. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $21.50.

About Orthofix Medical

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.